STOKNasdaqPharmaceutical PreparationsUS GAAP · USD

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing RNA-targeted medicines for severe genetic diseases. Its pipeline includes zorevunersen (STK-001) for Dravet syndrome, STK-002 for autosomal dominant optic atrophy, and additional product candidates developed through its TANGO platform and collaboration structure.

Kysy yhtiöstä
Liikevaihto184milj. USD
+404,5 %v/v
Liikevoitto (EBIT)−20,6milj. USD
+79,7 %v/v
EBIT-marginaali−11,2%
+266,1 %-yks.v/v
Nettotulos−6,9milj. USD
+92,3 %v/v
Vapaa kassavirta44,9milj. USD
+151,6 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−200−1000100200milj. USD2020: EBIT −53 milj. USD20202021: EBIT −86 milj. USD20212022: 12 milj. USD2022: EBIT −104 milj. USD20222023: 8,8 milj. USD2023: EBIT −115 milj. USD20232024: 37 milj. USD2024: EBIT −101 milj. USD20242025: 184 milj. USD2025: EBIT −21 milj. USD2025184−21
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Stoke Therapeutics, Inc.

Liiketoiminta

Osuus liikevaihdosta
Lead clinical programs70 %

Drug candidates in human clinical development, including zorevunersen and STK-002.

Collaboration and licensing revenue30 %

Revenue earned from licensing IP and performing partnered development activities.

Asiakkaat

Stoke’s direct commercial customers are not yet established because its products are still in development; instead, revenue currently comes from collaboration partners such as Biogen and Acadia. If approved, its medicines would be prescribed by healthcare providers and reimbursed by third-party payors, with access shaped by specialty neurology and rare-disease treatment pathways.

Strategic collaboration partners

Biogen and Acadia fund, develop, and potentially commercialize selected programs under alliance terms.

Neurologists and specialty prescribers

Physicians treating Dravet syndrome or other rare genetic disorders who would prescribe approved products.

Third-party payors

Commercial and government payors that would influence access, reimbursement, and uptake.

Rare-disease patients

Patients with severe genetic disorders who are the intended beneficiaries of the therapies.

Strategia

Stoke’s strategy centers on advancing its RNA-targeted rare-disease pipeline through clinical development and regulatory milestones. It also uses alliances to share development and commercialization responsibilities, especially outside North America, while preserving flexibility to build its own sales capability if products are approved.

Advance zorevunersen toward approvalLyhyt aikaväli

It is the company’s most advanced and strategically important program.

Develop and de-risk STK-002 and other pipeline assetsKeskipitkä aikaväli

Broader pipeline success reduces dependence on a single lead program.

Leverage partnerships for commercializationKeskipitkä aikaväli

Alliances extend geographic reach and reduce the need for a large internal sales force.

Maantiede

Stoke is headquartered in the United States and conducts its core research and development activities from there. Its commercial footprint is expected to be split between North America and ex-North America through partnerships, with Biogen covering development and commercialization outside North America for zorevunersen.

Riskit

Stoke is an early-stage biotechnology company, so its value depends heavily on successful clinical development, regulatory approval, and eventual commercialization of a small number of programs. It also faces financing, partnership execution, intellectual property, and healthcare reimbursement risks that are typical for rare-disease drug developers but especially important given its limited operating history.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Regulatory approval risk2Partner commercialization risk3Financing and dilution risk4Intellectual property risk5Healthcare compliance risk6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen

    Lead programs may not show sufficient safety or efficacy in later-stage trials.

    KohdistuuZorevunersenSTK-002
  2. Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    FDA or foreign regulators may delay, restrict, or deny approval.

    Kohdistuu: All product candidates

  3. Partner commercialization riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Biogen, Acadia, or future partners may not devote enough resources to launch and marketing.

    Kohdistuu: Ex-North America and partnered programs

  4. Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company expects to need additional capital to fund development and operations.

    Kohdistuu: Corporate funding

  5. Intellectual property riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Protection of RNA platform and product rights is essential to commercialization value.

    KohdistuuTANGO platformProduct candidates
  6. Healthcare compliance riskVaikutus: KeskitasoTodennäköisyys: Matala

    Future sales and distribution arrangements must comply with anti-kickback and fraud laws.

    Kohdistuu: U.S. commercialization

Kysy Clarifolta: Stoke Therapeutics, Inc.

Kirjanpito

Harkinnanvaraiset erät
Collaboration and license revenue recognition

Revenue depends on timing of performance obligations under Acadia and Biogen agreements.

Vaikutus: Can create large quarter-to-quarter swings in reported revenue

Clinical development cost estimation

R&D accruals and trial-related expenses depend on estimates of work performed and vendor billing.

Vaikutus: Affects operating expense timing and comparability

Stock-based compensation

Equity awards are a recurring non-cash expense for a development-stage biotech.

Vaikutus: Influences reported operating loss and dilution analysis

Impairment and valuation judgments

Pipeline assets, licenses, and other intangibles may require fair value or impairment assessments.

Vaikutus: Could affect future earnings if asset values change

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Spruce Biosciences, Inc

SPRB · Pharmaceutical Preparations

Neurogene Inc.

NGNE · Pharmaceutical Preparations

Biogen Inc

BIIB · Biological Products, (No Diagnostic Substances)

Arrowhead Pharmaceuticals, Inc

ARWR · Pharmaceutical Preparations

Spero Therapeutics, Inc.

SPRO · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Stoke Therapeutics, Inc. (Nasdaq) – Pharmaceutical Preparations | Analyysi – Clarifo